Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT02944175
Other study ID # MD /16.07.22
Secondary ID
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date July 2016
Est. completion date October 1, 2019

Study information

Verified date October 2018
Source Mansoura University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Cholinesterase inhibitors such as Neostigmine and Edrophonium have been used to reverse neuromuscular blockade after surgery. However, these drugs have a relatively slow onset and have adverse effects associated with stimulation of muscarinic receptors. In addition, neostigmine cannot be used to reverse profound blockade.

Anesthetics may exert their effects on various facets of cerebral function such as cerebral metabolic rate (CMRO2), cerebral blood flow (CBF), cerebral blood flow-metabolism coupling, intra cranial pressure (ICP), autoregulation, vascular response to CO2 and brain electrical activity. The net result of all these effects of the anaesthetic agents combined with their systemic effects may prove beneficial or detrimental to an already diseased brain.

In neurosurgical patients, clear and rapid recovery is required to early assess the neurological status and to maintain the cerebral oxygenation and metabolism within the normal physiological values which may be saved by sugammadex.


Description:

The aim of this study is to compare Sugammadex versus neostigmine as a reversal to the neuromuscular blockade of rocuronium in patients undergoing supratentorial tumors resection. Comparison will include hemodynamics, respiratory effort and degree of sedation.

Indicators of global cerebral oxygenation and haemodynamics will be calculated using jugular bulb and peripheral arterial blood sampling.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 40
Est. completion date October 1, 2019
Est. primary completion date September 1, 2019
Accepts healthy volunteers No
Gender All
Age group 20 Years to 60 Years
Eligibility Inclusion Criteria:

- American Society of Anesthesiologists physical class status I - III .

- Patients scheduled for elective supratentorial brain tumor resection

Exclusion Criteria:

- Severe uncompensated cardiac disease.

- Severe uncompensated respiratory disease.

- Severe uncompensated hepatic disease.

- Severe uncompensated renal disease.

- Morbidly obese patients.

- Documented hypersensitivity to one of the used drugs.

- Surgery in sitting position

- Surgery in prone position

- Patients with altered level of consciousness.

- Pregnancy.

Study Design


Related Conditions & MeSH terms

  • Supratentorial Brain Tumor Surgery

Intervention

Drug:
Sugammadex
At the end of surgery and when 2 responses were achieved on the TOF stimulation, Sugammadex 2 mg·kg-1 was administered intravenously in Group S
Neostigmine
At the end of surgery and when 2 responses were achieved on the TOF stimulation neostigmine 0.05 mg·kg-1 + atropine 0.02 mg·kg-1 was administered intravenously

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Mansoura University

Outcome

Type Measure Description Time frame Safety issue
Primary Time to recovery of the train-of-four (TOF) ratio to 0.9 The time from start of administration of sugammadex or neostigmine to recovery of the train-of-four (TOF) ratio to 0.9 For 1 hour after surgery
Secondary Arterio-Jugular oxygen content difference Ca jO2 = CaO2-CjvO For 6 hours after the start of surgery
Secondary Estimated cerebral metabolic rate for oxygen (eCMRO2) eCMRO2=Ca- jO2 x(PaCO2 / 100) Where ……. Ca jO2 is arterio-jugular O2 content difference.
PaCO2 is arterial CO2 tension
For 6 hours after the start of surgery
Secondary Cerebral Extraction Rate of Oxygen (CEO2) Calculated as the differences between arterial and jugular bulb O2 saturations, CEO2 = SaO2 - SjvO2 For 6 hours after the start of surgery
Secondary Cerebral Blood Flow equivalent (CBFe) Which is an index of flow metabolism relationship, calculated as a reciprocal of arterio-jugular O2 content difference For 6 hours after the start of surgery
Secondary Heart rate For 6 hours after the start of surgery
Secondary Blood pressure For 6 hours after the start of surgery
Secondary Central venous pressure For 6 hours after the start of surgery
Secondary Peripheral oxygen saturation For 6 hours after the start of surgery
Secondary End-tidal carbon dioxide tension For 6 hours after the start of surgery
Secondary Sedation level For 1 hour after extubation
Secondary Total dose of neuromuscular blockade used For 6 hours after the start of surgery
Secondary Total dose of suggamadex or neostigmine used For 30 min after the end of surgery
Secondary Cumulative opioids consumption For 6 hours after the start of surgery
Secondary Recovery time (RT) the time of restoration of neuromuscular conduction sufficient for extubation from stoppage of anaesthesia till the patient can obey commands For 1 hour after surgery
Secondary Time between administration of sugammadex or neostigmine to recovery Time from start of administration of sugammadex or neostigmine to recovery of the train-of-four (TOF) ratio to 0.9 For 1 hour after surgery